Clinical trialNCT01296711TerminatedPhase 2Interventional

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

SponsorUCB BIOSCIENCES, Inc.Enrollment190Rheumatoid Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the long term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis who completed study RA0056 (NCT01242488).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mark Genovese, Dr
Stanford University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

55 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium

401
Brussels, Belgium
400
Liège, Belgium

United Kingdom

206
Essex, United Kingdom
208
Southampton, United Kingdom
209
Torquay, United Kingdom

United States

166
Mesa, Arizona, United States
154
Phoenix, Arizona, United States
118
Scottsdale, Arizona, United States
103
Hot Springs, Arkansas, United States
127
Covina, California, United States
148
La Jolla, California, United States
184
Long Beach, California, United States
177
Los Angeles, California, United States
104
Palo Alto, California, United States
129
Santa Maria, California, United States
164
Upland, California, United States
141
Hamden, Connecticut, United States
111
Lewes, Delaware, United States
151
DeBary, Florida, United States
114
Jupiter, Florida, United States
157
Tampa, Florida, United States
183
Tampa, Florida, United States
116
Idaho Falls, Idaho, United States
160
Moline, Illinois, United States
168
Springfield, Illinois, United States
133
Cedar Rapids, Iowa, United States
172
Kansas City, Kansas, United States
185
Saint Clair Shores, Michigan, United States
112
St Louis, Missouri, United States
134
St Louis, Missouri, United States
102
Lincoln, Nebraska, United States
171
Freehold, New Jersey, United States
152
Toms River, New Jersey, United States
174
Brooklyn, New York, United States
170
Charlotte, North Carolina, United States
150
Cincinnati, Ohio, United States
100
Dayton, Ohio, United States
110
Oklahoma City, Oklahoma, United States
165
Duncansville, Pennsylvania, United States
105
Nashville, Tennessee, United States

15 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CDP6038

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Mar 2011
Primary completion: 1 May 2013
Completion: 5 Aug 2013
Last update posted: 14 Apr 2022
Registered enrollment: 190
Registry id: NCT01296711

Cross-registrations

EU-CTR / CTIS (EudraCT)2010-022224-77

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.